The pharmacogenetics of alcohol use disorder.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Alcoholism: Clinical and Experimental Research

• Publication date

  2015-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/acer.12643PMID 25703505PMCID PMC4348335
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self‐administration in young adults

  2016influential reference
• Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate

  2014cited by this paper
• Genome-wide association study of alcohol dependence:significant findings in African- and European-Americans including novel risk loci

  2014cited by this paper
• Association of Gamma-Aminobutyric Acid A Receptor α2 Gene (GABRA2) with Alcohol Use Disorder

  2014cited by this paper
• A GABRA2 variant is associated with increased stimulation and 'high' following alcohol administration.

  2014cited by this paper
• Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial.

  2014cited by this paper
• Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcohol

  2014influential reference
• Pharmacotherapy of alcohol use disorders: seventy-five years of progress.

  2014cited by this paper
• The clinical pharmacology of acamprosate

  2014cited by this paper
• Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism.

  2014cited by this paper
• Topiramate Treatment of Heavy Drinkers: Moderation by a GRIK1 Polymorphism

  2014cited by this paper
• Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.

  2014cited by this paper
• ALDH2*2 but not ADH1B*2 is a causative variant gene allele for Asian alcohol flushing after a low-dose challenge: correlation of the pharmacokinetic and pharmacodynamic findings

  2014cited by this paper
• GABRA2 markers moderate the subjective effects of alcohol

  2013influential reference
• Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase.

  2013cited by this paper
• Subjective response to alcohol among alcohol-dependent individuals: effects of the μ-opioid receptor (OPRM1) gene and alcoholism severity.

  2013influential reference
• Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment

  2013cited by this paper
• Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.

  2013cited by this paper
• Candidate Gene Studies of a Promising Intermediate Phenotype: Failure to Replicate

  2013cited by this paper
• Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.

  2013cited by this paper
• Interacting Effects of Naltrexone and OPRM1 and DAT1 Variation on the Neural Response to Alcohol Cues

  2013cited by this paper
• Variation in Mu-Opioid Receptor Gene (OPRM1) as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort.

  2013cited by this paper
• A large-scale meta-analysis of the association between the ANKK1/DRD2 Taq1A polymorphism and alcohol dependence

  2013cited by this paper
• Association of µ‐opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta‐analysis

  2012influential reference
• Preliminary Evidence for cue-induced Alcohol Craving Modulated by Serotonin Transporter Gene Polymorphism rs1042173

  2012cited by this paper
• Haplotype analysis of DRD2 and ANKK1 gene polymorphisms in alcohol dependence

  2012cited by this paper
• Pharmacogenetics of Naltrexone in Asian Americans: A Randomized Placebo-Controlled Laboratory Study

  2012influential reference
• Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.

  2012influential reference
• Genetic architectures of psychiatric disorders: the emerging picture and its implications

  2012cited by this paper
• Ethnicity interacts with the OPRM1 gene in experimental pain sensitivity

  2012cited by this paper
• Personalized Treatment of Alcohol Dependence

  2012cited by this paper
• Reduced dopamine receptor sensitivity as an intermediate phenotype in alcohol dependence and the role of the COMT Val158Met and DRD2 Taq1A genotypes.

  2012cited by this paper
• A large-scale meta-analysis of the association between the ANKK1/DRD2 Taq1A polymorphism and alcohol dependence

  2012cited by this paper
• Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.

  2012influential reference
• The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype.

  2011influential reference
• Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.

  2011influential reference
• A Double-Blind, Randomized Trial of Sertraline for Alcohol Dependence: Moderation by Age of Onset and 5-Hydroxytryptamine Transporter-Linked Promoter Region Genotype

  2011cited by this paper
• The association between the SLC6A3 VNTR 9-repeat allele and alcoholism-a meta-analysis.

  2011cited by this paper
• Variation in genes encoding the neuroactive steroid synthetic enzymes 5α-reductase type 1 and 3α-reductase type 2 is associated with alcohol dependence.

  2011cited by this paper
• Role of GABRA2 in moderating subjective responses to alcohol.

  2011cited by this paper
• Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society

  2010cited by this paper
• Opioid antagonists for alcohol dependence.

  2010cited by this paper
• Medication treatment of different types of alcoholism.

  2010cited by this paper
• Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.

  2010cited by this paper
• Genetic and environmental influences on cannabis use initiation and problematic use: a meta-analysis of twin studies.

  2010cited by this paper
• GENETIC STUDY: Interaction of SLC6A4 and DRD2 polymorphisms is associated with a history of delirium tremens

  2010cited by this paper
• Opioid antagonists for alcohol dependence.

  2010cited by this paper
• A population-based twin study of the genetic and environmental relationship of major depression, regular tobacco use and nicotine dependence

  2010cited by this paper
• Acamprosate for alcohol dependence

  2010cited by this paper
• A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.

  2009cited by this paper
• Effect of the allelic variants of aldehyde dehydrogenase ALDH2*2 and alcohol dehydrogenase ADH1B*2 on blood acetaldehyde concentrations

  2009cited by this paper
• Typologies of Alcohol Dependence. From Jellinek to Genetics and Beyond

  2009cited by this paper
• CLINICAL STUDY: Predicting the effect of naltrexone and acamprosate in alcohol‐dependent patients using genetic indicators

  2009cited by this paper
• Association of markers in the 3' region of the GluR5 kainate receptor subunit gene to alcohol dependence.

  2009cited by this paper
• The Sensitizing Effect of Tetraethylthiuramdisulphide (Antabuse) to Ethylalcohol.

  2009cited by this paper
• An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.

  2008cited by this paper
• The alcoholic phenotypes among different multidimensional typologies: similarities and their classification procedures.

  2008cited by this paper
• A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients

  2008influential reference
• Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.

  2008cited by this paper
• Alcohol use disorders in the DSM-V: the task ahead.

  2007cited by this paper
• Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.

  2007cited by this paper
• Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence.

  2007cited by this paper
• The alcohol withdrawal syndrome

  2007cited by this paper
• Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.

  2007cited by this paper
• Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case–control studies and evidence of publication bias

  2007cited by this paper
• Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis.

  2006cited by this paper
• Lack of Association of 5-HTTLPR Genotype with Smoking Cessation in a Nicotine Replacement Therapy Randomized Trial

  2006cited by this paper
• Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

  2006cited by this paper
• The human serotonin1A receptor exhibits G-protein-dependent cell surface dynamics

  2006cited by this paper
• Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

  2006cited by this paper
• Genetic moderators of naltrexone's effects on alcohol cue reactivity.

  2006cited by this paper
• Increased Attributable Risk Related to a Functional μ-Opioid Receptor Gene Polymorphism in Association with Alcohol Dependence in Central Sweden

  2005cited by this paper
• Association of the dopamine transporter gene with alcoholism.

  2005cited by this paper
• Medications for treating alcohol dependence.

  2005cited by this paper
• The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: Alternative biallelic variation in rhesus monkeys

  2005cited by this paper
• Alcohol-induced motor impairment caused by increased extrasynaptic GABAA receptor activity

  2005cited by this paper
• GABRA2 Alleles Moderate the Subjective Effects of Alcohol, Which are Attenuated by Finasteride

  2005cited by this paper
• A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans.

  2004cited by this paper
• Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology

  2004cited by this paper
• Alcohol withdrawal syndrome.

  2004cited by this paper
• Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations.

  2004influential reference
• The 12-Month Prevalence and Trends in DSM–IV Alcohol Abuse and Dependence

  2004cited by this paper
• Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1

  2004influential reference
• The role of GABAA receptors in mediating the effects of alcohol in the central nervous system.

  2003cited by this paper
• A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.

  2003cited by this paper
• A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients

  2003cited by this paper
• New pharmacotherapies for alcohol dependence

  2002cited by this paper
• The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression

  2001cited by this paper
• The role of GABAergic neuroactive steroids in ethanol action, tolerance and dependence.

  2001cited by this paper
• Treatment of alcohol-dependent outpatients with acamprosate: a clinical review.

  2001cited by this paper
• Towards a molecular epidemiology of alcohol dependence: analysing the interplay of genetic and environmental risk factors.

  2001cited by this paper
• Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal.

  2001cited by this paper
• Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals.

  2001cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  2001cited by this paper
• The Harvard Twin Study of Substance Abuse: what we have learned.

  2001cited by this paper
• The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants

  2000cited by this paper
• Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins.

  2000cited by this paper
• A population-based twin study in women of smoking initiation and nicotine dependence

  1999cited by this paper
• Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins.

  1999cited by this paper
• Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency.

  1999cited by this paper

• Altered Expression of Neuroplasticity-Related Genes in Alcohol Addiction and Treatment

  2024cites this paper
• Gut microbiome in alcohol use disorder: Implications for health outcomes and therapeutic strategies-a literature review

  2024cites this paper
• Risk behaviors in substance use disorder in a sample of Egyptian female patients with or without symptoms of attention-deficit hyperactivity disorder

  2023cites this paper
• Genetic Influences on Alcohol Sensitivity: a Critical Review

  2023cites this paper
• Association of Alcohol Use Disorder Risk With ADH1B, DRD2, FAAH, SLC39A8, GCKR, and PDYN Genetic Polymorphisms

  2022cites this paper
• Genetic Variability of Incretin Receptors and Alcohol Dependence: A Pilot Study

  2022cites this paper
• Pituitary adenylate cyclase-activating polypeptide type 1 receptor within the nucleus accumbens core mediates excessive alcohol drinking in alcohol-preferring rats

  2022cites this paper
• The Utility of Research Domain Criteria in Diagnosis and Management of Dual Disorders: A Mini-Review

  2022cites this paper
• The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine’s effects

  2022cites this paper
• Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder

  2022cites this paper
• Clinical Neuroscience of Addiction: What Clinical Psychologists Need to Know and Why.

  2021cites this paper
• Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: A randomized trial

  2021cites this paper
• Carnitine in Alcohol Use Disorders: A Scoping Review

  2021cites this paper
• Alcohol Use Disorder: The Role of Medication in Recovery

  2021cites this paper
• The Biopsychosocial Perspective and Research Methods for Investigation of Substance Use Disorders

  2020cites this paper
• Opioid Use Disorders

  2020cites this paper
• Tranquilizers and Sedative Use Disorders

  2020cites this paper
• Behavioral, Cognitive, and Social Factors Promoting SUD

  2020cites this paper
• Genetic Influence on Substance Use Disorders

  2020cites this paper
• Preface

  2020cites this paper
• Diagnosis of Substance Use Disorders

  2020cites this paper
• Brain Function and Substance Use Disorders

  2020cites this paper
• References

  2020cites this paper
• Treatment of Substance Use Disorders

  2020cites this paper
• Alcohol Use Disorders

  2020cites this paper
• Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant

  2020cites this paper
• Tobacco Use and Nicotine Addiction

  2020cites this paper
• Regulatory Aspects of Genomic Medicine and Pharmacogenomics

  2020cites this paper
• Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatment Outcomes.

  2020cites this paper
• Psychopharmacology

  2020cites this paper
• Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.

  2020cites this paper
• Substance Use Disorders

  2020cites this paper
• Psychiatric Disorders, Personality, and Developmental Factors

  2020cites this paper
• Cannabis Use Disorders

  2020cites this paper
• Use Disorders of Cocaine and Methamphetamine

  2020cites this paper
• Alcohol

  2019cites this paper
• Mini Review: Socio-Cultural Influences on the Link Between ADHD and SUD

  2019cites this paper
• Outcome Assessment in Trials of Pharmacological Treatments for Alcohol Use Disorders: Fair and Strict Testing

  2019cites this paper
• Molecular correlates of topiramate and GRIK1 rs2832407 genotype in pluripotent stem cell-derived neural cultures

  2019cites this paper
• Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice.

  2019cites this paper
• Baclofen in the Treatment of Alcohol Use Disorder

  2019cites this paper
• Pharmacogenetics of alcohol use disorder treatments: an update

  2019cites this paper
• Medication Development: Reducing Casualties in the Valley of Death and Providing Support for Survivors.

  2018cites this paper
• A prospective, longitudinal study to evaluate the clinical utility of a predictive algorithm that detects risk of opioid use disorder

  2018cites this paper
• Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review

  2018cites this paper
• Treatment for Alcohol Use Disorder: Progress in Predicting Treatment Outcome and Validating Nonabstinent End Points.

  2018cites this paper
• Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders

  2018cites this paper
• Advances in Pharmacotherapy Development: Human Clinical Studies.

  2018cites this paper
• Explicating the role of empathic processes in substance use disorders: A conceptual framework and research agenda

  2018cites this paper
• Advancing Pharmacotherapy Development from Preclinical Animal Studies.

  2018cites this paper
• Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders

  2018cites this paper
• Validation Study of a Predictive Algorithm to Evaluate Opioid Use Disorder in a Primary Care Setting

  2017cites this paper
• Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.

  2017cites this paper
• Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision

  2017cites this paper
• AAV Gene Therapy for Alcoholism: Inhibition of Mitochondrial Aldehyde Dehydrogenase Enzyme Expression in Hepatoma Cells

  2017cites this paper
• The effects of alcohol on neurotransmitters appear to mediate the risk for alcohol use disorder : a brief update

  2017cites this paper
• Precision medicine and pharmacogenetics: what does oncology have that addiction medicine does not?

  2017cites this paper
• ADHD, Lifestyles and Comorbidities: A Call for an Holistic Perspective – from Medical to Societal Intervening Factors

  2017cites this paper
• Prospective, Longitudinal Study to Evaluate the Clinical Utility of a Predictive Algorithm to Detect Opioid Use Disorder in Chronic Pain Patients

  2017cites this paper
• Gene expression profiling in the human alcoholic brain.

  2017cites this paper
• The Demon Drink

  2017cites this paper
• The confirmation of genetic variants associated with the subjective response after alcohol consumption

  2017cites this paper
• Zebrafish Models of Alcohol Addiction

  2017cites this paper
• Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders.

  2016cites this paper
• Genetic Counseling for Alcohol Use Disorder: Assessment of Need in Affected and At-Risk Populations

  2016cites this paper
• Studies on new pharmacological treatments for alcohol dependence - and the importance of objective markers of alcohol consumption

  2016cites this paper
• Potential Medications for the Treatment of Alcohol Use Disorder: An Evaluation of Clinical Efficacy and Safety

  2016cites this paper
• Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development.

  2016cites this paper
• Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development.

  2016cites this paper
• Subjective Response to Alcohol as a Research Domain Criterion.

  2016cites this paper
• Opioid Use Disorders.

  2016cites this paper
• Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment.

  2016cites this paper
• Comorbid alcohol and mental health disorders: a longitudinal analysis of development to young adulthood

  2015cites this paper
• A review of pharmacogenetic studies of substance-related disorders.

  2015cites this paper
• Decreased [3H]naloxone Binding in the Dentate Gyrus of Cloninger Type 1 Anxiety-Prone Alcoholics: A Postmortem Whole-Hemisphere Autoradiography Study.

  2015cites this paper
• Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders.

  2015cites this paper
• The Disease Concept

  1967cites this paper
• World Journal of Psychiatry

  year unknowncites this paper